NIKKEI 225
38,630.75 -316.18 (-0.81%) HANG SENG
19,272.36 +51.74 (+0.27%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,420.20 -5.70 (-0.23%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,921.46 -925.05 (-1.66%)
Organogenesis Holdings Inc. (ORGO)
After hours:
| Previous close | 2.7700 |
| Open | 2.7600 |
| Bid | 2.7400 x 500 |
| Ask | 2.7700 x 400 |
| Day's range | 2.7400 - 2.8450 |
| 52-week range | 1.9600 - 4.7050 |
| Volume | |
| Avg. volume | 1,095,662 |
| Market cap | 367.224M |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | 69.25 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million co
- GlobeNewswire
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance of function at six monthsTransformational opportunity for Organogenesis to enter large and growing pain management market with innovative therapyWill address critical unmet medical need for all knee OA patients, including the most severe, if approved CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine com
- GlobeNewswire
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Management will host a conference call at 5:00 p.m. Eastern Time on May 9th to
